868-68-8

Usage

Uses

Used in Chemical Research and Synthesis:
Diethyl 2,6-dibromoheptanedioate is used as a chemical intermediate for the synthesis of various compounds. Its unique structure with two bromine atoms attached to a benzene ring makes it a valuable building block in the preparation of complex organic molecules.
Used in Industrial Applications:
Diethyl 2,6-dibromoheptanedioate is employed in various industrial processes, where its chemical properties are utilized to achieve specific outcomes. Diethyl 2,6-dibromoheptanedioate's versatility and reactivity contribute to its use in the production of different products, such as pharmaceuticals, agrochemicals, and specialty chemicals.

InChI:InChI=1/C11H18Br2O4/c1-3-16-10(14)8(12)6-5-7-9(13)11(15)17-4-2/h8-9H,3-7H2,1-2H3

Upstream product

• 111-16-0 heptanedioic acid 
• 64-17-5 ethanol 
• 2050-20-6 diethyl pimelate 

Downstream Products

• 3128-16-3 cyclopent-2-ene-1,2-dicarboxylic acid 
• 3128-15-2 cyclopent-1-ene-1,2-dicarboxylic acid 
• 71550-71-5 1-hydroxy-cyclopentane-1,2-dicarboxylic acid 
• 3205-94-5 1-cyclopentene-1,2-dicarboxylic anhydride 
• 124-04-9 Adipic acid 
• 229466-66-4 Diethyl 2-(m-chlorobenzoyloxy)selenane-2,6-dicarboxylate 
• 229466-72-2 Diethyl 2-(m-chlorobenzoyloxy)-3,4-dihydro-2H-selenine-2,6-dicarboxylate 

Relevant academic research and scientific papers

NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE

This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Synthesis of a key intermediate in the diaminopimelate pathway to L-lysine: 2,3,4,5-tetrahydrodipicolinic acid

2,3,4,5-Tetrahydrodipicolinic acid (3) is a key intermediate in the diaminopimelate (DAP) pathway to L-lysine (7). It was synthesized as the stable racemic potassium salt (25) from dipicolinic acid (14) by esterification, hydrogenation to the cis-diester (17), followed by elimination of p-toluenesulfinic acid from the N-toluenesulfonyl derivative (24) of dimethyl cis-piperidine-2,6-dicarboxylate with concomitant cleavage of the esther groups. (±)-2,3,4,5-Tetrahydrodipicolinic acid is unstable in neutral or acidic solution, and in basic solution it exists in equilibrium with the corresponding enamine (27) and 2-oxo-6-aminoadipate (26).